CCL5 and atherosclerosis: Administration of the CC chemokine antagonist METRANTES (Veillard et al., 2004) or treatment with [44AANA47]-RANTES (Braunersreuther et al., 2008) inhibits the progression of atherosclerosis in a hyperlipidemic mouse model.